Karyopharm Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Karyopharm Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Karyopharm Therapeutics Inc Strategy Report
- Understand Karyopharm Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Karyopharm Therapeutics Catalyst Calendar
Proactively evaluate Karyopharm Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Karyopharm Therapeutics Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 May 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Mar 2020 | Phase III Trial Results | Argint International Kft; Excel Life Sciences; Karyopharm Therapeutics Inc; PPD Inc | KPTI | selinexor | Oncology | Multiple Myeloma (Kahler Disease); Refractory Multiple Myeloma; Relapsed Multiple Myeloma | Company Press Release |
| 31 Dec 2019 | NDA/BLA Filing (US) | Karyopharm Therapeutics Inc | KPTI | selinexor | Oncology | Diffuse Large B-Cell Lymphoma | Investment Bank Report |
| 20 Dec 2019 | Phase I/II Trial Completion | Karyopharm Therapeutics Inc; Washington University School of Medicine | KPTI | cladribine; cytarabine; plerixafor; selinexor | Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer